S

Syensqo SA
XBRU:SYENS

Watchlist Manager
Syensqo SA
XBRU:SYENS
Watchlist
Price: 70.17 EUR -2.43% Market Closed
Market Cap: 7.4B EUR
Have any thoughts about
Syensqo SA?
Write Note

Net Margin
Syensqo SA

0.3%
Current
2%
Average
4.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0.3%
=
Net Income
21m
/
Revenue
8.5B

Net Margin Across Competitors

Country BE
Market Cap 7.3B EUR
Net Margin
0%
Country US
Market Cap 99.8B USD
Net Margin
11%
Country JP
Market Cap 11.2T JPY
Net Margin
21%
Country US
Market Cap 70.4B USD
Net Margin
13%
Country CH
Market Cap 35.8B CHF
Net Margin
15%
Country US
Market Cap 35B USD
Net Margin
7%
Country CN
Market Cap 230.5B CNY
Net Margin
8%
Country CH
Market Cap 27.9B EUR
Net Margin
20%
Country US
Market Cap 28.6B USD
Net Margin
8%
Country IN
Market Cap 2.4T INR
Net Margin
14%
Country DK
Market Cap 165.6B DKK
Net Margin
17%
No Stocks Found

Syensqo SA
Glance View

Market Cap
7.3B EUR
Industry
Chemicals

Syensqo SA stands at the forefront of the biotechnology sector, driven by a vision to revolutionize disease treatment through advanced therapeutic solutions. Founded in the heart of an innovation hub, the company specializes in developing cutting-edge synthetic biology applications aimed at enhancing drug efficacy and reducing side effects. With a dynamic pipeline populated by promising drug candidates in various stages of clinical trials, Syensqo is harnessing the power of gene editing and novel delivery systems, creating a compelling narrative of growth and potential. Its strategic partnerships with leading research institutions and pharmaceutical companies underscore a commitment to collaboration and innovation, positioning Syensqo as a promising player in an ever-evolving market. For investors, Syensqo SA embodies both opportunity and sustainability. The company’s robust intellectual property portfolio not only protects its innovations but also provides a competitive edge in emerging markets. With a dedicated team of scientists and industry veterans at the helm, Syensqo is primed to navigate the complexities of regulatory landscapes while leveraging data-driven insights to guide decision-making. As the global demand for effective healthcare solutions escalates, Syensqo's commitment to sustainable practices and ethical drug development resonates strongly with socially conscious investors. By investing in Syensqo, stakeholders are not only placing their capital in a high-growth venture but also participating in a transformative journey toward groundbreaking healthcare advancements.

SYENS Intrinsic Value
115.61 EUR
Undervaluation 39%
Intrinsic Value
Price
S

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0.3%
=
Net Income
21m
/
Revenue
8.5B
What is the Net Margin of Syensqo SA?

Based on Syensqo SA's most recent financial statements, the company has Net Margin of 0.3%.